Toremifene

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Toremifene

Clinical data
ATC code	L02BA02 (WHO)
Pharmacokinetic data
Protein binding	more than 99.5%
Elimination half-life	5 days
Identifiers
IUPAC name 2-[4-(4-chloro-1, 2-diphenyl-but-1-enyl)phenoxy]- N,N-dimethyl-ethanamine
CAS Number	89778-26-7
PubChem CID	3005573
DrugBank	APRD00391
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C26H28ClNO
Molar mass	405.959 g/mol

WikiDoc Resources for Toremifene
Articles
Most recent articles on Toremifene Most cited articles on Toremifene Review articles on Toremifene Articles on Toremifene in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Toremifene Images of Toremifene Photos of Toremifene Podcasts & MP3s on Toremifene Videos on Toremifene
Evidence Based Medicine
Cochrane Collaboration on Toremifene Bandolier on Toremifene TRIP on Toremifene
Clinical Trials
Ongoing Trials on Toremifene at Clinical Trials.gov Trial results on Toremifene Clinical Trials on Toremifene at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Toremifene NICE Guidance on Toremifene NHS PRODIGY Guidance FDA on Toremifene CDC on Toremifene
Books
Books on Toremifene
News
Toremifene in the news Be alerted to news on Toremifene News trends on Toremifene
Commentary
Blogs on Toremifene
Definitions
Definitions of Toremifene
Patient Resources / Community
Patient resources on Toremifene Discussion groups on Toremifene Patient Handouts on Toremifene Directions to Hospitals Treating Toremifene Risk calculators and risk factors for Toremifene
Healthcare Provider Resources
Symptoms of Toremifene Causes & Risk Factors for Toremifene Diagnostic studies for Toremifene Treatment of Toremifene
Continuing Medical Education (CME)
CME Programs on Toremifene
International
Toremifene en Espanol Toremifene en Francais
Business
Toremifene in the Marketplace Patents on Toremifene
Experimental / Informatics
List of terms related to Toremifene

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

GTx Inc. is currently conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008